secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001104659-23-086806
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M
------------------------------------------------------------------------------

- GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.
- Net product sales $15.7M (GIAPREZA $11.2M, XERAVA $4.5M); $3.0M license milestone from XACDURO FDA approval.
- Net income $1.3M ($0.02 basic EPS) vs $0.9M ($0.01) in Q2 2022; cash + receivables $254M.
- Repurchased 775,504 shares for $9.2M in Q2 2023; invested $25M in Armata (NYSE: ARMP) on July 11, 2023.
- On May 23, 2023, FDA approved XACDURO for HABP/VABP caused by Acinetobacter; launch expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/0001104659-23-086806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/tm2322589d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer